Breast Cancer, Drug/Agent Toxicity by Tissue/Organ
Conditions
Keywords
stage I breast cancer, stage II breast cancer, stage IIIA breast cancer, recurrent breast cancer, drug/agent toxicity by tissue/organ
Brief summary
RATIONALE: Herbs used in traditional Chinese medicine may decrease the side effects of chemotherapy. PURPOSE: Randomized phase I/II trial to study the effectiveness of herbs used in traditional Chinese medicine in decreasing the side effects of chemotherapy after surgery in women who have stage I, stage II, or early stage III breast cancer.
Detailed description
OBJECTIVES: * Determine the toxic effects and safety of chinese herbal therapy (CHT) when administered for toxicity attenuation in combination with adjuvant doxorubicin and cyclophosphamide in women with stage I, II, or early stage III breast cancer. * Determine patient compliance and the feasibility of using CHT by daily treatment calendars, weekly symptom inventories, and quality of life and mood state questionnaires completed by these patients. * Determine patient preferences and concerns about CHT. * Determine, preliminarily, the efficacy of CHT in ameliorating the toxic effects/side effects of adjuvant chemotherapy with doxorubicin and cyclophosphamide, in terms of the incidence and severity of adverse events, in these patients. OUTLINE: This is a randomized, placebo-controlled, double-blind study. Patients are randomized to one of two treatment arms. * Arm I: Patients receive adjuvant doxorubicin IV and cyclophosphamide IV over 1 hour on days 0, 21, 42, and 63. Patients also receive oral chinese herbal therapy three times daily on days -10 to 105. * Arm II: Patients receive adjuvant chemotherapy as in arm I and oral placebo three times daily on days -10 to 105. Quality of life is assessed at baseline and on days 3, 24, 45, 66, 84, and 105. Patients are followed at day 105. PROJECTED ACCRUAL: A total of 60 patients (30 per treatment arm) will be accrued for this study.
Interventions
DIETARY_SUPPLEMENTChinese herbs
DRUGcyclophosphamide
DRUGdoxorubicin hydrochloride
PROCEDUREadjuvant therapy
Sponsors
National Cancer Institute (NCI)
University of California, San Francisco
Study design
Allocation
RANDOMIZED
Primary purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
DISEASE CHARACTERISTICS: * Histologically confirmed stage I, II, or early stage III breast cancer for which adjuvant doxorubicin and cyclophosphamide is recommended * No metastatic disease * Hormone receptor status: * Not specified PATIENT CHARACTERISTICS: Age: * Over 18 Sex: * Female Menopausal status: * Not specified Performance status: * Karnofsky 80-100% Life expectancy: * Not specified Hematopoietic: * WBC at least 3,000/mm\^3 * Absolute neutrophil count at least 1,500/mm\^3 * Hemoglobin at least 9.0 g/dL * Platelet count at least 100,000/mm\^3 Hepatic: * Bilirubin no greater than 1.5 mg/dL * AST no greater than 2 times normal Renal: * Creatinine no greater than 1.5 mg/dL Cardiovascular: * No evidence of acute ischemic cardiac disease on ECG Other: * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * No history of multiple severe food or medicine allergies or sensitivities * No medical or psychological condition that would preclude study participation * No severe concurrent illness PRIOR CONCURRENT THERAPY: Biologic therapy: * No concurrent immunotherapy Chemotherapy: * See Disease Characteristics * No other concurrent chemotherapy Endocrine therapy: * No concurrent hormonal therapy Radiotherapy: * At least 3 weeks since prior radiotherapy * No concurrent radiotherapy Surgery: * Not specified Other: * At least 3 weeks since prior investigational agents * At least 3 weeks since prior herbal therapy * No other concurrent investigational agents * No other concurrent herbal therapy or alternative medicine * Concurrent acupuncture allowed
Countries
United States
Outcome results
None listed